Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255970 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL18255972 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL18255974 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL632811 | 0.80 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL632812 | 0.80 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL634756 | 0.80 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL633987 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL5511774 | 0.80 | MTNR1B (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL5511776 | 0.80 | MTNR1B (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B | |
| SCHEMBL5511779 | 0.80 | MTNR1B (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
| EP-2245028-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | PIK3CD 3587/4885PIK3CA 3742/4885PIK3CB 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.